| Name | Title | Contact Details |
|---|---|---|
Jonathan Grandon |
Vice President and Division General Counsel | Profile |
The DePuy Synthes Companies offer the world’s most comprehensive portfolio of orthopaedic and neuro products and services for joint reconstruction, trauma, spine, sports medicine, neuro, cranio-maxillofacial, power tools and biomaterials. Each of the companies that comprise DePuy Synthes Companies has a celebrated history, and each has evolved to meet the needs of the changing orthopaedics and neuro marketplace. The history that weaves the fabric of the DePuy Synthes Companies is one that is rich with innovation and demonstrates sustained leadership in an ever-changing landscape of patient and professional needs. The content from the DePuy Synthes Companies LinkedIn page is informational only. This content is not a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician with questions regarding a medical condition. Reliance on information provided herein is at your own risk. Comments which are off-topic, offensive, or promotional, are prohibited. Neither DePuy Synthes Companies nor any of its operating companies are responsible for third-party materials appearing on the DePuy Synthes Companies page, including but not limited to linked third-party videos, linked third-party sites, and third-party advertisements. DePuy Synthes Companies does not control or endorse this third-party content and makes no representations regarding its accuracy.
American Medical Industrial Su is a Huntington, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MediCepts is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnpod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet`s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and https://www.omnipodeurope.com.* *Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long term, as it already does in the United States and Canada.
OMNIlife science, Inc. (Main) is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.